E
ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
STO:EXPRS2
Price:
5.3
SEK
1.15%
Market Cap:
kr18.7m
Balance Sheet
Balance Sheet Decomposition
ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB
Balance Sheet Decomposition is not available for
ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB
Balance Sheet
ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB
Currency: SEK
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
6
|
2
|
6
|
5
|
107
|
37
|
111
|
58
|
82
|
48
|
|
| Cash |
0
|
0
|
0
|
6
|
2
|
6
|
5
|
107
|
37
|
111
|
58
|
82
|
48
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
102
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
3
|
4
|
3
|
5
|
4
|
4
|
4
|
5
|
7
|
11
|
11
|
13
|
8
|
|
| Accounts Receivables |
2
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
|
| Other Receivables |
1
|
4
|
3
|
3
|
3
|
3
|
3
|
5
|
5
|
10
|
10
|
11
|
7
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
10
|
1
|
1
|
2
|
|
| Total Current Assets |
3
|
5
|
4
|
12
|
6
|
11
|
10
|
112
|
146
|
132
|
69
|
95
|
58
|
|
| PP&E Net |
1
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
5
|
6
|
8
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
9
|
8
|
7
|
6
|
4
|
3
|
3
|
2
|
2
|
2
|
|
| Goodwill |
0
|
0
|
0
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
1
|
1
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
4
|
5
|
4
|
|
| Other Assets |
0
|
0
|
0
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
4
N/A
|
5
+33%
|
4
-25%
|
25
+502%
|
17
-30%
|
21
+22%
|
19
-11%
|
119
+535%
|
152
+28%
|
137
-10%
|
79
-43%
|
105
+33%
|
65
-38%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
1
|
0
|
2
|
1
|
0
|
1
|
1
|
2
|
2
|
12
|
2
|
8
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
1
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
0
|
0
|
1
|
|
| Other Current Liabilities |
2
|
2
|
7
|
3
|
2
|
4
|
10
|
14
|
4
|
18
|
9
|
29
|
24
|
|
| Total Current Liabilities |
2
|
3
|
10
|
4
|
2
|
5
|
12
|
18
|
7
|
31
|
11
|
38
|
28
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
6
|
6
|
6
|
5
|
0
|
0
|
1
|
1
|
1
|
|
| Deferred Income Tax |
0
|
0
|
0
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
6
|
0
|
0
|
0
|
0
|
3
|
3
|
1
|
0
|
0
|
|
| Total Liabilities |
2
N/A
|
3
+44%
|
10
+222%
|
12
+16%
|
10
-11%
|
13
+21%
|
20
+56%
|
24
+23%
|
12
-52%
|
34
+193%
|
13
-61%
|
40
+201%
|
29
-27%
|
|
| Equity | ||||||||||||||
| Common Stock |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
3
|
3
|
4
|
6
|
12
|
16
|
|
| Retained Earnings |
1
|
2
|
7
|
8
|
18
|
35
|
52
|
87
|
129
|
240
|
470
|
217
|
0
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
20
|
24
|
42
|
49
|
178
|
266
|
339
|
530
|
270
|
207
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
240
|
470
|
217
|
187
|
|
| Total Equity |
2
N/A
|
2
+22%
|
6
N/A
|
13
N/A
|
7
-48%
|
8
+23%
|
1
N/A
|
95
N/A
|
140
+48%
|
103
-26%
|
65
-37%
|
65
-1%
|
36
-45%
|
|
| Total Liabilities & Equity |
4
N/A
|
5
+33%
|
4
-25%
|
25
+502%
|
17
-30%
|
21
+22%
|
19
-11%
|
119
+535%
|
152
+28%
|
137
-10%
|
79
-43%
|
105
+33%
|
65
-38%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
6
|
6
|
6
|
10
|
11
|
13
|
15
|
30
|
1
|
1
|
2
|
3
|
4
|
|
Switch to:
Switch to:
See Also
Discover More
